scholarly journals Reduced Final Height Outcome in Congenital Adrenal Hyperplasia under Prednisone Treatment: Deceleration of Growth Velocity during Puberty

2007 ◽  
Vol 92 (5) ◽  
pp. 1635-1639 ◽  
Author(s):  
Walter Bonfig ◽  
Susanne Bechtold ◽  
Heinrich Schmidt ◽  
Dietrich Knorr ◽  
Hans Peter Schwarz
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Growth Velocity ◽  
Final Height ◽  
Adrenal Hyperplasia ◽  
Prednisone Treatment

Near-final height in 82 Chinese patients with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency: a single-center study from China

2016 ◽  
Vol 29 (7) ◽  
Author(s):  
Lin Juan ◽  
Ma Huamei ◽  
Su Zhe ◽  
Li Yanhong ◽  
Chen Hongshan ◽  
...  
Keyword(s):  
Treatment Group ◽  
Congenital Adrenal Hyperplasia ◽  
Early Treatment ◽  
Final Height ◽  
Adrenal Hyperplasia ◽  
Target Height ◽  
Hydroxylase Deficiency ◽  
Cox Regression Analysis ◽  
Late Treatment ◽  
21 Hydroxylase Deficiency

AbstractThe objective of this study was to identify variables that might interfere with reaching the near final height (NFH) in Congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency (21-OHD).A cross-sectional study of 82 (24 males and 58 females) classic (23 salt-wasting form [SW] and 59 simple-virilizing form [SV]) CAH 21-OHD patients seen in our institution between 1989 and 2015 with 10.6 (0.5~25.5) years of follow-up who reached their NFH was conducted. The variables related to NFH were explored.NFH (153.35±8.31) cm, (–1.9±1.1) SD was significantly lower than the normal population (p<0.001). The treated patients reached a significantly higher NFH (–1.7±1.1) SD than those untreated (–2.6±1.0) SD (p<0.05). Both of early treatment and late treatment group were taller than untreated group (p<0.001, p=0.013, respectively), and early treatment group had a taller height trend than late treatment group (p=0.089). A better height outcome was observed in patients with advantage in target height, good compliance, and low hydrocortisone dose by multivariate Cox regression analysis in 62 treatment patients. NFH and hydrocortisone dose was negatively correlated (r=–0.23, p=0.078) in treated group. Patients complicated by central precocious puberty (CPP) received gonadotropin-releasing hormone analogue (GnRHa) plus letrozole had increased NFH with height SD for bone age and Ht SD improved after treatment compare to no intervention group (p=0.001, p=0.035).Patients with classic 21-OHD have blunted final height, as compared with their target height and the population norm, not-treated even worse. Careful treatment adjustments have a favorable influence on growth. Alternative treatments, such as the use of puberty inhibitors GnRHa in addition to anti-estrogen therapy letrozole can somewhat improve NFH in children with 21-OHD complicated by CPP.

Growth Patterns and Final Height in Congenital Adrenal Hyperplasia due to Classical 21-Hydroxylase Deficiency

2001 ◽  
Vol 55 (4) ◽  
pp. 161-171 ◽  
Author(s):  
Gábor Hargitai ◽  
János Sólyom ◽  
Tadej Battelino ◽  
Jan Lebl ◽  
Zuzanna Pribilincová ◽  
...  
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Final Height ◽  
Growth Patterns ◽  
Adrenal Hyperplasia ◽  
Hydroxylase Deficiency ◽  
21 Hydroxylase Deficiency

scholarly journals Final height of a group of patients with congenital adrenal hyperplasia

2013 ◽  
Author(s):  
Marta Ferreira ◽  
Sonia Santos ◽  
Ester Pereira ◽  
Beatriz Vale ◽  
Rita Cardoso ◽  
...  
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Final Height ◽  
Adrenal Hyperplasia
Sign in / Sign up

Export Citation Format

Share Document